Recent News

June 15, 2020

Noctrix Health granted FDA Breakthrough Device Designation for wearable Restless Legs Syndrome Therapy

Noctrix Health, Inc., a privately held medical device company announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its wearable NTX100 Neuromodulation therapy designed for the treatment of adults with primary moderate-seve...
June 08, 2020

Eisai Announces U.S. Availability of DAYVIGO® (lemborexant) CIV, a New Treatment Option for Adults With Insomnia

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced the availability of DAYVIGO® (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance
June 04, 2020

AAHS 2020 PJ5K Canceled

Due to the current COVID-19 (coronavirus) pandemic, the AAHS 2020 PJ5K has been canceled. Contact the AAHS at with any questions.